# Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

> **NCT01520389** · PHASE1 · COMPLETED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 112 (actual)

## Conditions studied

- Advanced Solid Tumors
- Colorectal Cancer
- Squamous Cell Head and Neck Cancer
- Non Small Cell Lung Cancer
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** MM-151
- **DRUG:** MM-151 + irinotecan

## Key facts

- **NCT ID:** NCT01520389
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2015-12
- **Final completion:** 2016-01
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2018-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01520389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01520389, "Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01520389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*